Dawson James Maintains Brainstorm Cell Therapeutics (BCLI) at Neutral, "NurOwn Efficacy, At Best, is Minimal"
Tweet Send to a Friend
Dawson James analyst Jason Kolbert reiterated a Neutral rating on Brainstorm Cell Therapeutics (NASDAQ: BCLI), following the company's Q1 report ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
